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Abstract Copper may be involved in the pathophysiology of
depression. Clinical data on this issue are very limited and not
conclusive. The purpose of the study was to determine the
copper concentration in the serum of patients with major de-
pressive disorder and to discuss its potential clinical usefulness
as a biomarker of the disease. A case–control clinical study
included 69 patients with current depressive episode, 45 pa-
tients in remission and 50 healthy volunteers. Cu concentration
was measured by electrothermal atomic absorption spectrome-
try (ETAAS). The mean serum copper level in depressed pa-
tients was slightly lower (by 11 %; not statistically significant)
than in the control group. Furthermore, there was no significant
difference in Cu2+ concentration between depressive episode
and remission, nor between remission and control group. In
the remission group were observed significant correlations
between copper levels and the average number of relapses over
the past years or time of remission. There was no correlation
between serum copper and severity of depression, as measured
by HDRS and MADRS. The obtained results showed no sig-
nificant differences between the copper concentration in the
blood serum of patients (both with current depressive episode
and in remission) and healthy volunteers, as well as the lack of
correlations between the copper level in the active stage of the
disease and clinical features of the population. Our study is the
first conducted on such a large population of patients, so the
results may be particularly important and reliable source of
knowledge about the potential role of copper in depression.
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Introduction
Copper (Cu) is the third most abundant trace metal (behind
iron and zinc) present in every tissue and is required for es-
sential body functions. As a cofactor for numerous enzymes, it
plays an important role in the biochemical processes, includ-
ing erythropoiesis, cellular respiration, peptide amidation,
iron, cholesterol and glucose metabolism, pigment formation,
and hormones biosynthesis (see [1] for review). These metal
ions are also necessary for the proper development and func-
tioning of the central nervous system; low copper level may
result in incomplete development, while excess concentration
maybe injurious [2]. Among the body organs, the brain is the
one of the most copper-rich (next to the heart and liver) [3].
The total human body contains only 75–100 mg, and the
recommended daily dosage for adult men and women is
0.9 mg/day (1–1.3 mg/day for pregnant or lactating women).
Copper is relatively a stable component of the blood, and its
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concentration usually remains between 100 and 130 mg/100 ml
of the serum [4, 5]. Approximately 90 % of the copper in the
blood is incorporated into ceruloplasmin, which is responsible
for carrying copper to tissues that need themineral [6, 7]. Proper
absorption and metabolism of copper requires an appropriate
balance with the minerals zinc and manganese. Because zinc
can compete with copper in the small intestine and interfere
with its absorption, persons who supplement with inappropri-
ately high levels of zinc and lower levels of coppermay increase
their risk of copper deficiency [8]. That is why the plasma/
serum ratio of copper to zinc (optimal 0.70–1.00) is clinically
more important than the blood concentration of either of these
trace metals. A crucial role in maintaining proper cellular zinc
and copper concentration play metallothioneins, which have the
capacity to bind both these ions through the thiol group of its
cysteine residues. In the human body, large quantities are syn-
thesized primarily in the liver and kidneys and their production
is dependent on availability of the dietary minerals [8].
Copper homeostasis is of great importance to human health.
Its imbalance is implicated directly or indirectly in the pathogen-
esis of numerous disorders. Deficit of Cu (rather rare and often
co-exist with other nutritional deficiencies)may affect connective
tissue leading to vascular and skeletal problems, causes neuronal
degeneration, anemia, and cardiac and immune dysfunctions.
Copper deficiency is associated with the following diseases:
aceruloplasminemia (very low or absence of ceruloplasmin),
Huppke–Brendl syndrome, familial amyotrophic lateral
sclerosis, Huntington’s disease, Menkes disease, and occipital
horn syndrome [9, 10]. In turn, excess amounts of copper may
result in cellular instability and damage due to the oxidative
potential of the free metal [5]. Copper toxicity symptoms
include nausea, vomiting, abdominal pain and cramps,
headache, dizziness, weakness, and diarrhea. High Cu
concentration is observed in Alzheimer’s, Parkinson’s, and
Wilson’s diseases and may also lead to decline in intelligence
in young adolescents [8, 9]. Limited data also suggests the
potential importance of copper in the development of
neuropsychiatric disorders, including depression [6, 11–16],
and several compelling arguments can confirm this fact.
Firstly, copper is an essential component of some enzymes
(monoamine oxidase—MAO, dopamine β-hydroxylaze—
DBH, and tyrosine hydroxylase) involved in the proper turn-
over of catecholamines, which disturbances can lead to the de-
velopment of depression [17, 18]. Secondly, copper concentra-
tion and even more balance between its reduced (Cu+) and
oxidized form (Cu2+) plays a fundamental role in the oxidative
and nitrosative stress (O&NS) processes, which may be one of
the main cause of mood disorders (e.g., major depressive disor-
der—MDD) [4, 8, 19, 20]. Furthermore, Cu is required for
structural and catalytic properties of some antioxidant enzymes
(e.g., lysyl oxidase and superoxidase dismutase), which are im-
portant free radical scavengers and prevent oxidative damages
of cells [5]. Many studies also suggest that induction of O&NS
pathways in depression is accompanied by activation of the
inflammatory response and acute phase (AP) proteins [21].
Thus, elevated serum concentration of ceruloplasmin (a key
protein involved in the storage of copper), a widely recognized
AP protein, in depressed patients may be a further evidence of
the potential role of Cu ions in the course of depression [22–24].
Copper concentration in the extracellular space is generally
low (0.2–1.7 μM), but during the neurotransmission in some
parts of the brain, it can raise even dozens of times. However,
the elevated levels of these ions may have important biological
significance. In particular, released of copper ions may inhibit
N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptor function
and thereby protect neurons from glutamatergic excitotoxity
[25–28]. The disturbances in glutamatergic transmission are
the basis of glutamate hypothesis of depression [29].
All the above data confirm the involvement of copper in the
regulation of important biological processes, which may be
critical in the development of mood disorders. So far, very
little is known about alterations in Cu concentration in depres-
sion. There are only few studies on this topic. Thus, we decid-
ed to measure the copper level in the blood serum of a rela-
tively large population of patients with MDD (depending on
the current stage of the disease) and to discuss its potential
clinical usefulness as a biomarker of the disease.
Methods
This study was a part of a large research project entitled BDe-
Me-Ter^ (depression–mechanisms–therapy), the aim of which
was to examine the relationship between the symptomatology
of affective disorders and the serum concentrations of some
biometals, inflammatory, and oxidative stress markers, poten-
tially involved in the pathophysiology of these diseases [30].
Recruitment of the Study Participants
The study participants were recruited among the in- and out-
patients of the Department of Psychiatry, University Hospital
(Jagiellonian University Medical College, Cracow, Poland) in
the period from 21 September 2006 to 30 July 2013.
The people meeting the DSM-IV-TR criteria for major de-
pressive disorder (MDD) (both in active phase and in remis-
sion) and healthy volunteers were included in the study. All
participants signed the informed consent forms and were pro-
vided with detailed information (both verbally and in writing)
about the aims and characteristics of the study. Each potential
study participant had the opportunity to ask questions about the
study before signing the consent and all those questions were
answered by the doctor responsible for the recruitment. The
Jagiellonian University Bioethics Committee have approved
this study (decision number KBET/77/B/2009; 25.06.2009).
288 Styczeń et al.
The exclusion criteria (selected on the basis of precise
history taking) were described in detail in our previous re-
port [30], but the main were as follows: lack of signed
consent; diagnosis of a severe psychiatric disorder other than
MDD (for example: schizophrenia, schizoaffective disorder,
bipolar disorder); addictive diseases (excluding addiction to
nicotine and caffeine); diagnosis of a severe personality dis-
order; presence of severe somatic disorders (acute or chron-
ic); breastfeeding; or pregnancy. During the study, all the
patients were receiving pharmacotherapy with proven effica-
cy (mono- or polytherapy; for more details, see [30]).
The control group was recruited through advertisements on
hospital notice boards, by referral from hospital staff, or their
relatives and friends. This group consisted of individuals with
no present and past history of severe and chronic somatic or
psychiatric diseases, without history of substance use disor-
ders (except for caffeine and nicotine abuse), and with no
psychiatric disorders in the first-degree relatives.
The Diagnostic Tools
The severity of depressive symptoms was measured with
the Montgomery–Asberg Depression Rating Scale—
MADRS [31] and the Hamilton Rating Scale for
Depression – HDRS [32].
Collection and Processing of Blood Samples
and Quantitative Analysis of Copper in Blood Serum
Samples
According to the study protocol, from each patient and healthy
volunteer no more than 9.8 ml of blood was obtained from a
brachial vein using the Monovette system. After the cloth
formation the blood samples were centrifuged for 30 min at
1800 RPM. The obtained serum samples were stored at
−80 °C until use.
After thawing, the serum copper levels were measured by a
electrothermal atomic absorption spectrometry—ET AAS.
The authors used Perkin Elmer spectometer Model 3110
(USA) equipped with a Perkin Elmer HGA-600 graphite fur-
nace. The following measurements’ conditions were used:
pretreatment temperature was set to 950 °C and atomization
to 2300 °C; the wavelength was set at 324.8 nm and slit to
0.7 nm. The samples were diluted appropriately to fit into the
linear range (10–50 ng/ml) of calibration curves. Standards
(Copper standard solution; Merck Millipore Corp.,
Darmstadt, Germany) and samples were prepared as water
solutions. Diluted samples were homogenized by means of
sonification. Despite dilution, no sample pretreatment proce-
dures were applied prior to quantitative elements determina-
tion. All the measurements were performed in triplicate. The
accuracy was tested by means of recovery analysis, which for
Cu was in the range of 96–103 %.
Statistical Methods
The χ2 test was used in order to analyze the differences
between the qualitative variables. The Shapiro–Wilk test
was performed in order to evaluate the normal distribution
of quantitative data. Because of the absence of the normal
distribution of data, we used the Kruskal–Wallis ANOVA
or the Mann–Whitney U test. Correlations between quan-
titative variables—due to lack of normal distribution—
were analyzed with the Spearman’s rank correlation.
Results
One hundred and fourteen patients (86 women and 28 men)
who met the DSM-IV-TR criteria for MDD (69 patients with
depressive episodes and 45 in remission) and 50 healthy peo-
ple (36 women and 14 men) were recruited for the case–con-
trol study. All of the patients were treated according to current
guidelines using the following drugs: selective serotonin re-
uptake inhibitors (SSRI), serotonin–norepinephrine selective
inhibitors (SNRI), tricyclic antidepressants (TCA), or
mirtazapine, except that some patients were additionally treat-
ed with atypical antipsychotic drugs (olanzapine or
quetiapine), lithium or lamotrigine to potentiate antidepressant
therapy. The detailed characteristics of the study participant
were presented in our previous report [30].
The mean age in the group of patients (49.36 ± 10.67) did
not show significant differences from the control group
(45.82 ± 12.43), (p = 0.064; Mann–WhitneyU test). Nor there
were any significant differences in terms of the gender distri-
bution (p = 0.64; χ2 test). The percentage of women in the
group of patients was 75.4 %, and in the control group 72 %.
There were no significant differences between the average
serum concentration of copper in women and in men
(p = 0.21; Mann–Whitney U test).
The mean scores in MADRS and HDRS among all the
MDD patients (in depressive episode and remission together)
were as follows: 17.64 ± 13.4 in MADRS and 13.02 ± 8.94 in
HDRS. The mean MADRS and HDRS scores of patients in
depressive group were 26.17 ± 9.74 and 18.83 ± 6.3, respec-
tively. Among patients in remission mean MADRS scores
were 4.25 ± 4.2, while HDRS 4.11 ± 3.14.
The analysis of variance indicated that there was no sig-
nificant influence of the disease nor affiliation to healthy
volunteer group on the obtained serum copper concentra-
tions (p > 0.05; Kruskal–Wallis test). The mean copper
levels in depression (0.81 ± 0.27 μg/ml) were lower than
in the control group (0.91 ± 0.39 μg/ml). However, this
difference was not statistically significant (p > 0.05).
Similar lack of significance (p > 0.05) in copper concentra-
tion was observed between depressive patients and those in
remission (1.01 ± 1.51 μg/ml) (Table 1).
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Detailed analysis of the data obtained from patients with a
various clinical picture of depressive episodes revealed that
there were no statistically significant difference (p > 0.05;
Mann–Whitney U test) in copper levels between patients with
or without the following clinical features: atypical symptoms
of depression, psychotic symptoms, melancholic syndrome,
or drug resistance (Table 2).
Another analysis also showed the lack of correlation be-
tween copper concentration in the depression or remission
phase and age of the patients and several clinical features:
duration of the disease; age at the onset of the disorder;
duration of the current depressive episode or remission; av-
erage number of depressive episodes in last year; and num-
ber of total hospitalization in over the past year and in the
lifetime. Only in the remission group significant correlation
was observed between the serum copper concentration and
the mean number of depressive episodes over the past year
and duration of the remission (r = 0.30 and r = −0.41, re-
spectively; p < 0.05).
The analysis of correlation between the copper levels and
the severity of depression (as measured with the HDRS/
MADRS total scores) showed no significance regardless of
the subsample (Table 3).
Discussion
In this case–control study we found that the mean serum cop-
per levels in patients with the depressive episode did not sig-
nificantly differ from those obtained in healthy volunteers
samples. Likewise, there were no significant differences be-
tween copper concentration in depressed patients with or
without such clinical features as: atypical features of depres-
sion, drug resistance, presence of psychotic symptoms or mel-
ancholic syndrome. The obtained copper concentrations
showed no correlation with many of the clinical features of
the disease. However, in the remission group we found signif-
icant correlation between serum copper levels and number of
episodes in last year or duration of the remission.
Until now, an analysis of copper concentration in the
blood of the patients diagnosed with MDD was the subject
of only a few case–control studies and all of them were
conducted on a smaller groups of patients [6, 12–16].
Manser et al. [12] in a study of Karachi population observed
elevated (by 22 %) plasma copper level in 31 (15 males, 16
females) depressed patients as compared to the 62 normal
healthy individuals. Similar observations were also made
later by Narang et al. [13]. In the study including 35 (21
males, 14 females) patients there were noted significantly
higher (by 14 %) Cu levels in depressed people than in
the healthy volunteers (n = 35). In turn, after recovery, plas-
ma copper concentration were significantly decreased (by
15 %) [13]. Both of these studies seem to be in opposition
to our results, which present no alterations in the level of
copper in the course of depression. On the other hand, an-
other study performed on a group of 31 depressed patients
and 15 healthy volunteers by Maes et al. [6] indicating no
change in copper concentration between the study groups.
Additionally, Maes et al. reported no difference in patients
meeting (or not) the criteria of melancholic syndrome or
drug resistance and no significant correlation between cop-
per levels and severity of depression, duration of depressive
episode, age at the onset or total duration of the disorder [6].
Those results remain in line with our study. However, in the
Table 1 Serum copper concentration [μg/ml] in MDD patients, depending on the current phase of the disease (depression or remission), and healthy
controls. Data are expressed as mean ± SD or Median [Upper/Lower quartile]
Depression Remission Control
Cu concentration [μg/ml] Mean ± SD
0.81 ± 0.27 1.01 ± 1.51 0.91 ± 0.39
Median [upper/lower quartile]
0.83 [0.58/1.00] 0.85 [0.69/0.96] 0.82 [0.68/1.04]
Table 2 Comparison of copper
serum concentrations [μg/ml;
mean concentration, and median
(upper/lower quantile)] in MDD
patients with a various clinical
picture of depressive episodes
Depression Mean ± SD Median
[upper/lower quartile]
Mann–Whitney
U test; p
With atypical features 0.70 ± 0.34 0.80 [0.46/0.93] 0.92
Without atypical features 0.93 ± 1.07 0.83 [0.68/0.99]
With melancholic features 0.82 ± 0.28 0.81 [0.58/1.03] 0.63
Without melancholic features 0.93 ± 1.19 0.84 [0.58/0.98]
With psychotic syndromes 0.73 ± 0.21 0.69 [0.56/0.90] 0.59
Without psychotic syndromes 0.89 ± 1.0 0.83 [0.64/1.0]
Drug-resistant 0.71 ± 0.28 0.66 [0.46/0.84] 0.21
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Maes et al.’s trial, there was a decline of copper levels in
depressive patients following the antidepressant treatment,
while we did not perform any corresponding analyses.
Partly consistent with our findings are also the results ob-
tained by Schlegel-Zawadzka et al. [15, 16]. Although, in
the study, which enrolled 19 MDD patients and 16 healthy,
was shown elevated levels of copper in depressed people.
However, just like in our study, there was not any correla-
tion between copper levels and severity of depression mea-
sured by HDRS, and moreover, effective antidepressant was
without effect on this measure [15, 16]. Interesting observa-
tions, which in part are consistent with our results, have also
been made in the cross-sectional analysis by Crayton and
Walsh [11], the study to which 813 (485 women and 328
men) depressed patients and 54 (28 women and 26 men)
control subjects between 30 and 60 years were selected;
significant increase in the serum copper concentration in
depressed women compared to the matched control was
demonstrated. Additionally, it has been shown that women
with a history of postpartum depression (PPD) exhibited
significantly higher Cu level than those without PPD history.
Simultaneously, no difference between the nondepressed and
depressed men, and moreover, lower copper levels in normal
men than in healthy women were observed. Unfortunately,
although this transversal study was conducted on a large
population, had a lot of limitations (e.g., absence of current
formal diagnostic evaluations or small size of the control
groups), which may undermine the potential usefulness of
these results [11].
In line with our observations seem to be also the results of
some animalmodels of depression (chronic severe stress, chron-
ic mild stress and olfactory bulbectomy), that revealed no alter-
ations in serum copper in relation to the control group [15].
Concluding, observed (not only) in our study, no signifi-
cant differences in the serum copper concentration between
the patients with the current episode of depression and healthy
volunteers, between remission and healthy control group, nor
the lack of correlation between the Cu level and severity of
depression (or clinical features of population) may suggest
that the role of this trace element in the pathophysiology of
major depressive disorder and thereby its potential usefulness
as a clinical marker of the disease seems to be relatively low.
On the other hand, the interpretation of our findings, apart
from the strengths of the study (many possible intervening
variables: age, sex, nicotine dependence, socio-demographic
data and the drug state of the patients) should also take into
account its restrictions: the lack of a prospective model to test
the dynamics of the copper concentrations in the same
patients, depending on the stage of the disease; substantial
heterogeneity (with regard to the applied therapy) of the study
groups and the relatively small number of subgroups
presenting specified clinical features. It is also important
to mention about significance of zinc/copper ratio, which
is crucial for proper functioning of human organism [8].
Some researcher suggest that zinc-copper imbalance can
lead to the development of many diseases, especially
psychiatric disorders (e.g., depression, postpartum depres-
sion, schizophrenia, autism spectrum disorders) and that
monitoring of Zn/Cu ratio may be clinically a more sensi-
tive and reliable marker than measuring of each element
separately [see 8 for review].
Regardless of this fact, no doubt, this study represents a
significant source of knowledge on this issue; however, in
view of many limitations and an extremely small number of
published reports (and ambiguity of results), our observations
should be confirmed by subsequent studies conducted on an
even larger (and also other) human population and allowing
for analysis of the impact of applied pharmacotherapy and
other clinical factors on the copper concentration.
Limitations
The main limitations of the presented study are the following:
lack of a prospective model to test the dynamics of changes in
copper levels in individual patients; considerable heterogene-
ity of the study groups in terms of treatment; and the small
number of subgroups presenting specified clinical features.
Table 3 Correlations between
serum copper concentration [μg/
ml] and selected quantitative
clinical features in depression and
remission (Spearman correlation,
*p < 0.05)
Cu [μg/ml]
MDD (Total) Depression Remission
Age −0.1 −0.08 −0.16
Age of disease onset −0.021 −0.06 0.009
Number of episodes in the life −0.012 0.1 0.18
The average annual number relapses in the last year 0.096 0.07 0.30
The disease duration −0.057 0.0001 −0.16
Duration of the episode /remission −0.177 −0.05 −0.41
Total MADRS score 0.001 0.013 0.03
Total HDRS score −0.001 0.04 0.012
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